Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Omega Therapeutics Inc (OMGA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: OMGA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -50.25% | Avg. Invested days 34 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 7.90M USD | Price to earnings Ratio - | 1Y Target Price 11.5 |
Price to earnings Ratio - | 1Y Target Price 11.5 | ||
Volume (30-day avg) 2612668 | Beta 1.64 | 52 Weeks Range 0.01 - 3.63 | Updated Date 03/27/2025 |
52 Weeks Range 0.01 - 3.63 | Updated Date 03/27/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.32 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -628.64% |
Management Effectiveness
Return on Assets (TTM) -25.02% | Return on Equity (TTM) -166.9% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 98708298 | Price to Sales(TTM) 0.98 |
Enterprise Value 98708298 | Price to Sales(TTM) 0.98 | ||
Enterprise Value to Revenue 12.19 | Enterprise Value to EBITDA -2.12 | Shares Outstanding 55366200 | Shares Floating 21734007 |
Shares Outstanding 55366200 | Shares Floating 21734007 | ||
Percent Insiders 1.67 | Percent Institutions 87.75 |
Analyst Ratings
Rating 4.43 | Target Price 9 | Buy 2 | Strong Buy 4 |
Buy 2 | Strong Buy 4 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Omega Therapeutics Inc
Company Overview
History and Background
Omega Therapeutics, founded in 2017, is a genomic medicine company pioneering a new class of programmable epigenetic medicines to treat and cure disease by leveraging its OMEGA platform.
Core Business Areas
- OMEGA Platform: Omega's core business revolves around its OMEGA (Orchestration of Methylation to Epigenetically Guide Activity) platform, which allows for the precision control of gene expression through targeted modulation of epigenetic processes. Their technology aims to address a wide range of diseases by selectively controlling gene activity.
Leadership and Structure
Mahesh Karande serves as President and Chief Executive Officer. The organizational structure includes departments for research and development, clinical operations, and business development.
Top Products and Market Share
Key Offerings
- OTX-2002: OTX-2002 is Omega's lead product candidate, an investigational first-in-class programmable epigenetic medicine (epigenomic controller) for the treatment of MYC-driven hepatocellular carcinoma (HCC). Market share data is not currently available as OTX-2002 is in clinical development. Competitors in HCC treatment include Bayer (BAYRY) with Sorafenib and Lenvima.
Market Dynamics
Industry Overview
The genomic medicine field is rapidly evolving, with significant investment and advancements in gene therapy, gene editing, and epigenetic modulation. There is a high demand for targeted therapies with improved efficacy and safety profiles.
Positioning
Omega Therapeutics is positioned as a pioneer in the field of programmable epigenetic medicines, leveraging a unique platform to target and control gene expression. Their competitive advantage lies in their ability to precisely modulate epigenetic processes.
Total Addressable Market (TAM)
The TAM for epigenetic therapies is estimated to be billions of dollars, with significant potential for growth as the field matures. Omega Therapeutics is positioned to capture a portion of this market by developing innovative treatments for a range of diseases.
Upturn SWOT Analysis
Strengths
- Novel OMEGA platform
- Strong intellectual property portfolio
- Experienced leadership team
- Potential for broad application across multiple diseases
Weaknesses
- Early stage of development
- High research and development costs
- Reliance on successful clinical trial outcomes
- Limited revenue generation currently
Opportunities
- Partnerships with pharmaceutical companies
- Expansion into new therapeutic areas
- Positive clinical trial results
- Advancements in epigenetic research
Threats
- Competition from other genomic medicine companies
- Regulatory hurdles
- Clinical trial failures
- Patent disputes
Competitors and Market Share
Key Competitors
- CRSP
- EDIT
- NTLA
- LLY
Competitive Landscape
Omega Therapeutics faces competition from companies developing gene editing and gene therapy technologies. Their competitive advantage lies in their unique epigenetic modulation platform.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Omega Therapeutics' historical growth is characterized by preclinical development and early clinical trials.
Future Projections: Future growth projections depend on the success of their clinical trials and regulatory approvals.
Recent Initiatives: Recent initiatives include advancing OTX-2002 into clinical trials and expanding their pipeline of epigenetic medicines.
Summary
Omega Therapeutics is an early-stage genomic medicine company with a novel platform for epigenetic modulation. Success depends on positive clinical trial outcomes. The company needs to be mindful of the risks associated with regulatory approval and competition within the genomic medicine space. Their unique platform offers the potential for significant growth if the clinical trials perform well.
Similar Companies
- CRSP
- EDIT
- NTLA
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Market Research Reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market conditions and company performance can change rapidly.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Omega Therapeutics Inc
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2021-07-30 | President, CEO & Director Dr. Kaan Certel Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 93 | Website https://omegatherapeutics.com |
Full time employees 93 | Website https://omegatherapeutics.com | ||
Omega Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company's OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences. It also develops OTX-2002 for hepatocellular carcinoma; OTX-2101 for non-small cell lung cancer; omega epigenomic controllers (OEC) for inflammatory lung diseases, such as neutrophilic asthma, acute respiratory distress syndrome, dermatological, oncology, and rheumatological indications; OEC candidates for idiopathic pulmonary fibrosis; liver regeneration medicines; and OEC candidates for patients with diabetes and other conditions to treat corneal epithelial injury. In addition, the company develops OEC candidates for the treatment of alopecia, a disorder characterized by patches of non-scarring hair loss affecting the scalp and body. Omega Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts. On February 10, 2025, Omega Therapeutics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.